Market Cap 77.91B
Revenue (ttm) 14.20B
Net Income (ttm) 4.41B
EPS (ttm) N/A
PE Ratio 20.36
Forward PE 21.39
Profit Margin 31.07%
Debt to Equity Ratio 0.06
Volume 804,800
Avg Vol 1,072,452
Day's Range N/A - N/A
Shares Out 105.10M
Stochastic %K 80%
Beta 0.37
Analysts Strong Sell
Price Target $791.15

Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to...

Industry: Biotechnology
Sector: Healthcare
Phone: 914 847 7000
Address:
777 Old Saw Mill River Road, Tarrytown, United States
RunnerSignals
RunnerSignals Dec. 13 at 4:25 PM
Golden crosses and sneaky reversals are popping up. $IIPR $REGN $NEM $CB $PLTR showing very different moods on the charts. charts have the clues https://stocksrunner.com/news/2025-12-13-daily-market-pulse-advanced-technical-analysis
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Dec. 12 at 8:24 PM
$REGN strong finish!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 12 at 6:13 PM
Enter: $REGN Calls Strike Price: $750 Expiry Date: JAN 02 2026 Buy in Price: $12.30 - $17.60 Sell Price: $28.29 Profit : +130% (Turn every $1 into $2.30) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 5:19 PM
Morgan Stanley has updated their rating for Regeneron Pharmaceuticals ( $REGN ) to Equal-Weight with a price target of 768.
0 · Reply
Trade_Force_5729
Trade_Force_5729 Dec. 12 at 5:18 PM
$REGN Mainz Biomed has a simple long game, guideline driven CRC screening plus a non invasive option, and the addressable population starts with USPSTF 45+ and runs through 75, that’s a massive funnel
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 12 at 3:17 PM
$REGN RSI: 45.69, MACD: 17.6617 Vol: 29.25, MA20: 734.72, MA50: 660.21 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:42 PM
Actionable Trade Alert for $REGN: Market Context: $REGN is currently trading at $736.15, positioned between its 60-day high of $790.98 and low of $541.00. The RSI at 49.77 indicates a neutral momentum, suggesting potential for upward movement. Directional Bias: The stock is above the 30-day MA of 705.94 and significantly above the 50-day MA of 657.73, indicating a bullish trend. The proximity to the 60-day high suggests upward momentum may continue. Trade Plan: - Suggested Entry: $740.00 - Stop Loss: $710.00 (4% below entry) - Take Profit Targets: 1. $770.00 (4% gain) 2. $800.00 (8% gain) 3. $865.00 (17% gain) With a stop loss at $710.00, the risk-reward ratio is favorable, providing a potential 17% ROI at the third target. Monitor market conditions closely for adjustments. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Dec. 11 at 9:57 PM
$REGN shorts have to be careful rolling into Friday...
0 · Reply
megan_hughes09
megan_hughes09 Dec. 11 at 7:54 PM
$REGN Mainz Biomed volume profile shows the bulk of shares traded from 1.37 to 2.00, but price is chilling around 1.06 - that’s a powder keg setup where any bullish catalyst can force trapped longs to chase up the ladder
0 · Reply
topstockalerts
topstockalerts Dec. 11 at 6:46 PM
Biohaven reported positive clinical data for its experimental cancer drug BHV-1510 in combination with Regeneron’s cemiplimab. In a Phase 1 study, the 2.5 mg/kg dose achieved a confirmed objective response rate of 72.7%, including 60% in non-small cell lung cancer, 100% in endometrial cancer, and 50% in urothelial cancer—remarkable given that most patients had previously progressed on PD-(L)1 inhibitors. The treatment showed a favorable safety profile versus other Trop2 ADCs, with low neutrophil declines and no interstitial lung disease; the most common side effect was manageable oral mucositis. BHV-1510 uses Biohaven’s TopoIx payload and targets Trop2, common in solid tumors. The Phase 1 trial enrolled 31 heavily pretreated patients, many of whom remain on therapy beyond six months, suggesting durable responses. Biohaven is expected to advance the drug into further trials following these encouraging early results. $BHVN $REGN
0 · Reply
Latest News on REGN
2 Reasons to Buy Regeneron Stock Like There's No Tomorrow

Dec 13, 2025, 10:01 AM EST - 16 hours ago

2 Reasons to Buy Regeneron Stock Like There's No Tomorrow


Should You Buy This Biotech Stock That Just Gained 5% in 1 Day?

Nov 30, 2025, 11:15 PM EST - 13 days ago

Should You Buy This Biotech Stock That Just Gained 5% in 1 Day?


Final Trade: LMAT, REGN, BA, TJX

Nov 12, 2025, 6:20 PM EST - 4 weeks ago

Final Trade: LMAT, REGN, BA, TJX

TJX BA LMAT


Regeneron Announces Investor Conference Presentations

Nov 3, 2025, 4:05 PM EST - 5 weeks ago

Regeneron Announces Investor Conference Presentations


2 Beaten-Down Stocks That Could Be About to Rally

Nov 3, 2025, 7:58 AM EST - 5 weeks ago

2 Beaten-Down Stocks That Could Be About to Rally

NVO


Market Starting To Embrace The 'New' Regeneron

Oct 29, 2025, 12:01 PM EDT - 6 weeks ago

Market Starting To Embrace The 'New' Regeneron


Has Regeneron Stock Quietly Become A Value Buy?

Oct 27, 2025, 8:35 AM EDT - 6 weeks ago

Has Regeneron Stock Quietly Become A Value Buy?


7 Stocks Taking The Next Step To Be On Offense

Oct 23, 2025, 7:30 PM EDT - 7 weeks ago

7 Stocks Taking The Next Step To Be On Offense

ACI BIO CNX FCF FDX FIS IAC


2 Stocks Down 17% and 21% to Buy Right Now

Oct 14, 2025, 10:00 AM EDT - 2 months ago

2 Stocks Down 17% and 21% to Buy Right Now

DXCM


11 Cheap Stocks for a Market That's Too Expensive

Oct 7, 2025, 11:49 AM EDT - 2 months ago

11 Cheap Stocks for a Market That's Too Expensive

DAL FDX UAL


Regeneron: Growth Catalysts Incoming

Sep 30, 2025, 4:25 PM EDT - 2 months ago

Regeneron: Growth Catalysts Incoming


2 Beaten-Down Stocks to Buy and Hold for a Decade

Sep 30, 2025, 7:30 AM EDT - 2 months ago

2 Beaten-Down Stocks to Buy and Hold for a Decade

MRNA


RunnerSignals
RunnerSignals Dec. 13 at 4:25 PM
Golden crosses and sneaky reversals are popping up. $IIPR $REGN $NEM $CB $PLTR showing very different moods on the charts. charts have the clues https://stocksrunner.com/news/2025-12-13-daily-market-pulse-advanced-technical-analysis
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Dec. 12 at 8:24 PM
$REGN strong finish!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 12 at 6:13 PM
Enter: $REGN Calls Strike Price: $750 Expiry Date: JAN 02 2026 Buy in Price: $12.30 - $17.60 Sell Price: $28.29 Profit : +130% (Turn every $1 into $2.30) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 5:19 PM
Morgan Stanley has updated their rating for Regeneron Pharmaceuticals ( $REGN ) to Equal-Weight with a price target of 768.
0 · Reply
Trade_Force_5729
Trade_Force_5729 Dec. 12 at 5:18 PM
$REGN Mainz Biomed has a simple long game, guideline driven CRC screening plus a non invasive option, and the addressable population starts with USPSTF 45+ and runs through 75, that’s a massive funnel
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 12 at 3:17 PM
$REGN RSI: 45.69, MACD: 17.6617 Vol: 29.25, MA20: 734.72, MA50: 660.21 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:42 PM
Actionable Trade Alert for $REGN: Market Context: $REGN is currently trading at $736.15, positioned between its 60-day high of $790.98 and low of $541.00. The RSI at 49.77 indicates a neutral momentum, suggesting potential for upward movement. Directional Bias: The stock is above the 30-day MA of 705.94 and significantly above the 50-day MA of 657.73, indicating a bullish trend. The proximity to the 60-day high suggests upward momentum may continue. Trade Plan: - Suggested Entry: $740.00 - Stop Loss: $710.00 (4% below entry) - Take Profit Targets: 1. $770.00 (4% gain) 2. $800.00 (8% gain) 3. $865.00 (17% gain) With a stop loss at $710.00, the risk-reward ratio is favorable, providing a potential 17% ROI at the third target. Monitor market conditions closely for adjustments. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Dec. 11 at 9:57 PM
$REGN shorts have to be careful rolling into Friday...
0 · Reply
megan_hughes09
megan_hughes09 Dec. 11 at 7:54 PM
$REGN Mainz Biomed volume profile shows the bulk of shares traded from 1.37 to 2.00, but price is chilling around 1.06 - that’s a powder keg setup where any bullish catalyst can force trapped longs to chase up the ladder
0 · Reply
topstockalerts
topstockalerts Dec. 11 at 6:46 PM
Biohaven reported positive clinical data for its experimental cancer drug BHV-1510 in combination with Regeneron’s cemiplimab. In a Phase 1 study, the 2.5 mg/kg dose achieved a confirmed objective response rate of 72.7%, including 60% in non-small cell lung cancer, 100% in endometrial cancer, and 50% in urothelial cancer—remarkable given that most patients had previously progressed on PD-(L)1 inhibitors. The treatment showed a favorable safety profile versus other Trop2 ADCs, with low neutrophil declines and no interstitial lung disease; the most common side effect was manageable oral mucositis. BHV-1510 uses Biohaven’s TopoIx payload and targets Trop2, common in solid tumors. The Phase 1 trial enrolled 31 heavily pretreated patients, many of whom remain on therapy beyond six months, suggesting durable responses. Biohaven is expected to advance the drug into further trials following these encouraging early results. $BHVN $REGN
0 · Reply
Nthwarning
Nthwarning Dec. 11 at 4:25 PM
$REGN Just shorted this pig. I’ll wait for a yr or two. Easy money from over exuberance and low intelligence MM. Did it with ANF CAR yr/yrs ago. and have CIEN REGN UNH currently short. waiting to short more CIEN and REGN if they can squeeze another $40-50 out of each of em. Stupid MM we can see you.
3 · Reply
amunka
amunka Dec. 11 at 3:45 PM
$REGN nice reversal guys!!
0 · Reply
RespectMyAuthoritah
RespectMyAuthoritah Dec. 11 at 3:38 PM
$REGN God damn😮‍💨😮‍💨😮‍💨
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Dec. 11 at 3:09 PM
$REGN let's get another $25 pt move today.
0 · Reply
Iwannagofast1
Iwannagofast1 Dec. 11 at 3:03 PM
$REGN my baby is going to 1000, where is the village idiot Johny at? so we do not see him around this board . He must still shoveling crap off the NY streets. let’s go REGN
1 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 11 at 2:18 PM
🎯 Target Hit 🏁 📨 From Dec 10, 2025 🏛️ $REGN 💵 Entry: $707.2300 ✅ Exit: $722.1526 💰 P/L: +2.11% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
Maxwell_Osgood
Maxwell_Osgood Dec. 11 at 12:55 AM
0 · Reply
PlumpComet
PlumpComet Dec. 10 at 9:30 PM
$REGN trading with calm stability
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 8:07 PM
Wells Fargo updates rating for Regeneron Pharmaceuticals ( $REGN ) to Equal-Weight, target set at 700 → 745.
0 · Reply
SPG565
SPG565 Dec. 10 at 5:42 PM
$REGN $PFE PFE would have to double to be valued the same as the reasonable valuation of REGN. Huge upside, you would think 🤔
1 · Reply
jdlman
jdlman Dec. 10 at 5:28 PM
$REGN why was this named top pick
1 · Reply
IN0V8
IN0V8 Dec. 10 at 4:39 PM
$REGN Wells Fargo raises target price to $745 from $700
0 · Reply